Agile licensing for drugs and devices

Summary#

Health Canada published a proposal called the Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing) in the Canada Gazette, Part I on December 17, 2022. The changes would let regulators attach enforceable conditions to drug and device approvals, introduce required risk-management plans, allow “rolling” reviews of some submissions, modernize rules for biologic drugs, and ask for certain clinical trial data by subgroup; the government estimates net benefits of $256 million (present value) over 10 years.

What it does#

• Gives the Minister of Health (through Health Canada) clear power to put enforceable “terms and conditions” (T&Cs) on any drug identification number or on Class II–IV medical device licences. T&Cs can be added at approval or later to require extra studies, monitoring or changes.
• Requires a risk management plan (RMP) for some human drugs when there is significant uncertainty about safety or a serious health risk. RMP summaries must be provided in both official languages.
• Creates a formal “rolling review” option so companies can file parts of a drug submission in stages, with deadlines for missing information (Health Canada mentions plans that must show how missing data will be provided within 155 days). Rolling reviews already used for some COVID-19 and influenza cases would be put into regulation and could be expanded to other urgent or highly promising drugs.
• Clarifies that drug fabrication, packaging, testing and storage (including during transport) must be done in a way that assures product quality (aligns with GMP expectations).
• Replaces many dated, product‑specific rules for biologic drugs with more flexible, outcome‑based requirements (keeping current practices like lot release and on‑site checks).
• Lets Health Canada consider information from inspections, on‑site evaluations, or foreign regulators when reviewing a submission.
• Requires manufacturers to submit clinical trial data broken down by population subgroups (age, sex, race, etc.) when that disaggregated data has already been provided to the US FDA or EMA.
• Eases some label and standards rules: in some cases manufacturers claiming their own standard would no longer have to meet the strictest limits from all pharmacopoeias and some label statements would be removed to free label space.
• Timing: several elements would come into force upon registration, while T&Cs for all drugs, full RMP requirements and some rolling‑review options would come into force one year after registration.

Who's affected#

• Drug manufacturers and medical device makers, including makers of biologics and vaccines.
• Generic drug companies (may save time and costs from relaxed standards and label rules).
• Clinical trial sponsors and companies that collect or submit trial data (because of subgroup data requirements).
• Importers, distributors, fabricators, packagers/labellers, testers and wholesalers (because of clarified quality and storage expectations).
• Health‑care providers and patients indirectly, through changes in oversight, availability and post‑market monitoring.
• Small businesses in the sector — Health Canada estimates about 225 small firms could be affected.
• The public consultation was open for 100 days after the notice (this is a proposal, not yet law).

Why it matters#

• Faster or more flexible approvals: rolling reviews and clearer procedures aim to get some important drugs to market sooner (Health Canada estimates an average of about two months earlier for a small set of qualifying drugs). That can matter for patients with urgent or rare conditions.
• Stronger post‑market control: T&Cs and RMPs give regulators enforceable ways to require further studies or safety measures after a product is on the market, which can keep potentially useful products available while protecting patients.
• Better information about who benefits and who is at risk: disaggregated trial data helps spot safety or effectiveness differences in women, older adults, racial groups and other under‑represented populations.
• Less outdated red tape for biologics and standards: replacing old product‑specific rules with outcome‑based requirements can reduce unnecessary burden on manufacturers and help prevent supply disruptions.
• Money and tradeoffs: Health Canada’s cost‑benefit summary estimates industry costs of $158 million, government costs of $26 million, for a total cost of $184 million, and benefits of $440 million (all PV over 10 years) yielding a net benefit of $256 million. Those are estimates and depend on how the rules are used in practice.
• This is a proposed regulatory package and was open for comment; it is not yet in force and some parts would only start later to allow the system to prepare.